Comparison of disease characteristics in clinical trial patients and historic controls
| Characteristic . | Toci (n = 45) . | No Toci (n = 39) . | P value . |
|---|---|---|---|
| Diagnosis, n (%) | .12 | ||
| AML | 21 (47%) | 29 (74%) | |
| ALL | 12 (27%) | 4 (10%) | |
| MPAL | 3 (7%) | 1 (3%) | |
| MDS | 4 (9%) | 1 (3%) | |
| CML | 2 (4%) | 3 (8%) | |
| NHL | 3 (7%) | 1 (3%) | |
| Diagnosis and disease status, n (%)∗ | |||
| AML/ALL/MPAL | n = 36 | n = 34 | .1 |
| CR1 | 34 (94) | 27 (80) | |
| CR2 | 2 (6) | 6 (18) | |
| Relapsed/refractory | 0 | 1 (3) | |
| MDS | |||
| <5% blasts | 2 (50) | 1 (100) | |
| >5% blasts | 2 (50) | 0 | |
| CML | |||
| Chronic phase CR | 2 (100) | 2 (67) | |
| Accelerated phase | 0 | 1 (33) | |
| NHL | |||
| CR | 2 | 1 | |
| PR | 1 | 0 | |
| Acute leukemia MRD status | n = 36 | n = 34 | .2 |
| CR MRD positive | 7 | 12 | |
| CR MRD negative | 24 | 19 | |
| CR MRD unknown | 5 | 2 | |
| Relapsed/refractory | 0 | 1 | |
| ELN2010 classification for AML | n = 21 | n = 29 | .8 |
| Favorable | 3 | 3 | |
| Intermediate-1 | 7 | 11 | |
| Intermediate-2 | 8 | 8 | |
| Adverse | 3 | 7 | |
| MDS genetic risk | n = 4 | n = 1 | |
| Standard risk | 1 | 1 | |
| Adverse risk | 3 | 0 |
| Characteristic . | Toci (n = 45) . | No Toci (n = 39) . | P value . |
|---|---|---|---|
| Diagnosis, n (%) | .12 | ||
| AML | 21 (47%) | 29 (74%) | |
| ALL | 12 (27%) | 4 (10%) | |
| MPAL | 3 (7%) | 1 (3%) | |
| MDS | 4 (9%) | 1 (3%) | |
| CML | 2 (4%) | 3 (8%) | |
| NHL | 3 (7%) | 1 (3%) | |
| Diagnosis and disease status, n (%)∗ | |||
| AML/ALL/MPAL | n = 36 | n = 34 | .1 |
| CR1 | 34 (94) | 27 (80) | |
| CR2 | 2 (6) | 6 (18) | |
| Relapsed/refractory | 0 | 1 (3) | |
| MDS | |||
| <5% blasts | 2 (50) | 1 (100) | |
| >5% blasts | 2 (50) | 0 | |
| CML | |||
| Chronic phase CR | 2 (100) | 2 (67) | |
| Accelerated phase | 0 | 1 (33) | |
| NHL | |||
| CR | 2 | 1 | |
| PR | 1 | 0 | |
| Acute leukemia MRD status | n = 36 | n = 34 | .2 |
| CR MRD positive | 7 | 12 | |
| CR MRD negative | 24 | 19 | |
| CR MRD unknown | 5 | 2 | |
| Relapsed/refractory | 0 | 1 | |
| ELN2010 classification for AML | n = 21 | n = 29 | .8 |
| Favorable | 3 | 3 | |
| Intermediate-1 | 7 | 11 | |
| Intermediate-2 | 8 | 8 | |
| Adverse | 3 | 7 | |
| MDS genetic risk | n = 4 | n = 1 | |
| Standard risk | 1 | 1 | |
| Adverse risk | 3 | 0 |
ELN2010, European LeukemiaNet 2010 genetic risk.
P values are omitted for MDS, CML, NHL, and MDS genetic risk because of the small sample size.